JP2021513541A5 - - Google Patents
Info
- Publication number
- JP2021513541A5 JP2021513541A5 JP2020542960A JP2020542960A JP2021513541A5 JP 2021513541 A5 JP2021513541 A5 JP 2021513541A5 JP 2020542960 A JP2020542960 A JP 2020542960A JP 2020542960 A JP2020542960 A JP 2020542960A JP 2021513541 A5 JP2021513541 A5 JP 2021513541A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- seq
- composition according
- pharmaceutical composition
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024000162A JP2024038251A (ja) | 2018-02-13 | 2024-01-04 | 抗ｐｄ－１抗体によるがんの処置方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862630038P | 2018-02-13 | 2018-02-13 | |
| US62/630,038 | 2018-02-13 | ||
| US201862732828P | 2018-09-18 | 2018-09-18 | |
| US62/732,828 | 2018-09-18 | ||
| PCT/US2019/017177 WO2019160751A2 (en) | 2018-02-13 | 2019-02-08 | Methods for treating cancer with anti-pd-1 antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024000162A Division JP2024038251A (ja) | 2018-02-13 | 2024-01-04 | 抗ｐｄ－１抗体によるがんの処置方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021513541A JP2021513541A (ja) | 2021-05-27 |
| JP2021513541A5 true JP2021513541A5 (enExample) | 2022-02-16 |
Family
ID=67620026
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020542960A Pending JP2021513541A (ja) | 2018-02-13 | 2019-02-08 | 抗ｐｄ−１抗体によるがんの処置方法 |
| JP2024000162A Pending JP2024038251A (ja) | 2018-02-13 | 2024-01-04 | 抗ｐｄ－１抗体によるがんの処置方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024000162A Pending JP2024038251A (ja) | 2018-02-13 | 2024-01-04 | 抗ｐｄ－１抗体によるがんの処置方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US12358984B2 (enExample) |
| EP (1) | EP3752180A4 (enExample) |
| JP (2) | JP2021513541A (enExample) |
| KR (1) | KR20200119844A (enExample) |
| CN (2) | CN111712255A (enExample) |
| AU (2) | AU2019220495B2 (enExample) |
| BR (1) | BR112020016331A8 (enExample) |
| CA (1) | CA3090995A1 (enExample) |
| CL (1) | CL2020002075A1 (enExample) |
| IL (1) | IL276303A (enExample) |
| MA (1) | MA52789A (enExample) |
| MX (2) | MX2020008445A (enExample) |
| SG (1) | SG11202007590TA (enExample) |
| WO (1) | WO2019160751A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101586617B1 (ko) | 2007-06-18 | 2016-01-20 | 머크 샤프 앤 도메 비.브이. | 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체 |
| CN112203642B (zh) | 2019-03-25 | 2025-03-07 | 阿特根公司 | 用于皮下注射的包含人透明质酸酶ph20变体和药物的药物组合物 |
| EP4034163A4 (en) * | 2019-09-27 | 2023-11-08 | Merck Sharp & Dohme LLC | METHOD FOR TREATING METASTASIC TRIPLE NEGATIVE BREAST CANCER USING ANTI-PD-1 ANTIBODIES |
| US20230355757A1 (en) | 2019-12-20 | 2023-11-09 | Formycon Ag | Formulations of anti-pd1 antibodies |
| EP4076521A4 (en) * | 2019-12-20 | 2024-01-24 | Merck Sharp & Dohme LLC | Methods for treating cancer using a combination of a pd-1 antagonist, an ilt4 antagonist, and chemotherapeutic agents |
| CN112326961B (zh) * | 2020-10-30 | 2021-08-06 | 福州迈新生物技术开发有限公司 | 一种非小细胞肺癌中pd-l1阳性肿瘤细胞比例的分析方法和存储设备 |
| CN112394102B (zh) * | 2020-11-05 | 2023-05-26 | 上海交通大学医学院附属瑞金医院 | 一种检测垂体功能减退症的标志物及其应用 |
| EP4359001A1 (en) | 2021-06-23 | 2024-05-01 | Formycon AG | Formulations of anti-pd1 antibodies |
| US20250011453A1 (en) * | 2021-07-20 | 2025-01-09 | Merck Sharp & Dohme Llc | Methods for treating cancer using a combination of a pd-1 antagonist, an ilt4 antagonist, and chemotherapeutic agents |
| CN113893343A (zh) * | 2021-10-16 | 2022-01-07 | 广州誉衡生物科技有限公司 | 抗-pd-1抗体及其在制备治疗宫颈癌患者的药物中的用途 |
| EP4449126A4 (en) * | 2021-12-16 | 2025-12-31 | Merck Sharp & Dohme Llc | BIOMARKERS THAT CAN PREDICT ELIGIBILITY FOR ANTI-ILT4 AND ANTI-PD-1 POLYTHERAPY |
| EP4637818A1 (en) | 2022-12-21 | 2025-10-29 | Formycon AG | Formulations of anti-pd1 antibodies |
| CN115925954A (zh) * | 2022-12-28 | 2023-04-07 | 广州誉衡生物科技有限公司 | 抗-pd-1抗体及其在制备治疗尿路上皮癌患者的药物中的用途 |
| WO2025140467A1 (zh) * | 2023-12-29 | 2025-07-03 | 上海复宏汉霖生物技术股份有限公司 | 稳定的高浓度抗pd-1抗体药物制剂 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| EP1135415B1 (en) | 1998-12-01 | 2010-08-11 | Facet Biotech Corporation | Humanized antibodies to gamma-interferon |
| WO2004056875A1 (en) | 2002-12-23 | 2004-07-08 | Wyeth | Antibodies against pd-1 and uses therefor |
| PL2161336T5 (pl) | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| KR101586617B1 (ko) * | 2007-06-18 | 2016-01-20 | 머크 샤프 앤 도메 비.브이. | 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체 |
| MX341076B (es) * | 2011-03-31 | 2016-08-04 | Merck Sharp & Dohme | Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados. |
| AR093984A1 (es) | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
| US20160084839A1 (en) | 2013-04-02 | 2016-03-24 | Marisa Dolled-Filhart | Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue |
| WO2015095423A2 (en) | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
| MA40344A (fr) * | 2014-07-18 | 2016-01-21 | Advaxis Inc | Combinaison d'un antagoniste de pd-1 et d'un vaccin à base de listeria pour le traitement du cancer |
| CA2955676A1 (en) | 2014-08-25 | 2016-03-03 | Pfizer Inc. | Combination of a pd-1 antagonist and an alk inhibitor for treating cancer |
| EP4098278A1 (en) * | 2014-11-13 | 2022-12-07 | The Johns Hopkins University | Checkpoint blockade and microsatellite instability |
| AR103726A1 (es) * | 2015-02-27 | 2017-05-31 | Merck Sharp & Dohme | Cristales de anticuerpos monoclonales anti-pd-1 humanos |
| WO2016176504A1 (en) * | 2015-04-28 | 2016-11-03 | Bristol-Myers Squibb Company | Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody |
| US11078278B2 (en) | 2015-05-29 | 2021-08-03 | Bristol-Myers Squibb Company | Treatment of renal cell carcinoma |
| EP3389712B1 (en) | 2015-12-17 | 2024-04-10 | Novartis AG | Antibody molecules to pd-1 and uses thereof |
| EP3405203A4 (en) | 2016-01-22 | 2019-07-24 | X4 Pharmaceuticals, Inc. | METHOD FOR THE TREATMENT OF CANCER |
| CN109196121B (zh) | 2016-02-29 | 2022-01-04 | 基因泰克公司 | 用于癌症的治疗和诊断方法 |
| WO2017165125A1 (en) * | 2016-03-24 | 2017-09-28 | Millennium Pharmaceuticals, Inc. | Use of a pd-1 antagonist and an anti-ccr2 antibody in the treatment of cancer |
| TWI786044B (zh) | 2016-05-13 | 2022-12-11 | 美商再生元醫藥公司 | 藉由投予ｐｄ-１抑制劑治療皮膚癌之方法 |
| WO2017205216A1 (en) * | 2016-05-23 | 2017-11-30 | Eli Lilly And Company | Combination of pembrolizumab and abemaciclib for the treatment of cancer |
| CN109476753A (zh) | 2016-06-03 | 2019-03-15 | 百时美施贵宝公司 | 用于治疗肿瘤的方法的抗-pd-1抗体 |
| HRP20201993T1 (hr) | 2016-09-14 | 2021-02-05 | Abbvie Biotherapeutics Inc. | Protutijela protiv pd-1 |
| EP3565844B8 (en) | 2017-01-09 | 2023-04-12 | Tesaro, Inc. | Methods of treating cancer with anti-pd-1 antibodies |
| JP7780857B2 (ja) * | 2017-06-01 | 2025-12-05 | ブリストル－マイヤーズ スクイブ カンパニー | 抗ｐｄ－１抗体を用いる腫瘍の治療方法 |
-
2019
- 2019-02-08 JP JP2020542960A patent/JP2021513541A/ja active Pending
- 2019-02-08 AU AU2019220495A patent/AU2019220495B2/en active Active
- 2019-02-08 SG SG11202007590TA patent/SG11202007590TA/en unknown
- 2019-02-08 BR BR112020016331A patent/BR112020016331A8/pt unknown
- 2019-02-08 CA CA3090995A patent/CA3090995A1/en active Pending
- 2019-02-08 CN CN201980013286.8A patent/CN111712255A/zh active Pending
- 2019-02-08 CN CN202511206047.8A patent/CN120919306A/zh active Pending
- 2019-02-08 KR KR1020207026004A patent/KR20200119844A/ko not_active Ceased
- 2019-02-08 US US16/966,968 patent/US12358984B2/en active Active
- 2019-02-08 MA MA052789A patent/MA52789A/fr unknown
- 2019-02-08 WO PCT/US2019/017177 patent/WO2019160751A2/en not_active Ceased
- 2019-02-08 MX MX2020008445A patent/MX2020008445A/es unknown
- 2019-02-08 EP EP19754909.0A patent/EP3752180A4/en active Pending
-
2020
- 2020-07-26 IL IL276303A patent/IL276303A/en unknown
- 2020-08-10 CL CL2020002075A patent/CL2020002075A1/es unknown
- 2020-08-12 MX MX2024013016A patent/MX2024013016A/es unknown
-
2023
- 2023-09-01 US US18/459,842 patent/US20240026003A1/en not_active Abandoned
-
2024
- 2024-01-04 JP JP2024000162A patent/JP2024038251A/ja active Pending
-
2026
- 2026-02-12 AU AU2026201041A patent/AU2026201041A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021513540A5 (enExample) | ||
| JP2020522486A5 (enExample) | ||
| JP2023027199A5 (enExample) | ||
| JP2024102215A5 (enExample) | ||
| JP2022506839A5 (enExample) | ||
| JP2018070648A5 (enExample) | ||
| JP2023507190A5 (enExample) | ||
| JP2018518454A5 (enExample) | ||
| JP2019535254A5 (ja) | 抗ｐｄ−ｌ１抗体および変異型 | |
| RU2018146886A (ru) | Пути терапевтического применения ингибитора c-raf | |
| JP2018503365A5 (enExample) | ||
| JP2024102055A5 (enExample) | ||
| RU2017117664A (ru) | Комбинация | |
| JP2020514310A5 (enExample) | ||
| JP2021510697A5 (enExample) | ||
| JP2025092589A5 (enExample) | ||
| JP2020502271A5 (enExample) | ||
| JP2021511372A5 (enExample) | ||
| JP2022512851A5 (enExample) | ||
| JP2024511137A5 (enExample) | ||
| CN108079292A (zh) | 一种抗pd-1抗体在制备治疗肝癌的药物中的用途 | |
| JP2023548430A5 (enExample) | ||
| JP2025507817A5 (enExample) | ||
| JP2024512574A5 (enExample) | ||
| JPWO2022270524A5 (enExample) |